On July 27, 2026 Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for cancer patients with inadequate therapeutic options, reported the acceptance of three abstracts for presentation at the 2026 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress, which will be held October 23-27 in Madrid.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The accepted presentations highlight clinical progress across Elevar’s pipeline:
Rivoceranib: A rapid oral presentation detailing Phase 2 results in pretreated metastatic thymic epithelial tumors.
Camrelizumab + Rivoceranib: A poster sub-analysis of the CARES-310 study evaluating the impact of early antibiotic exposure on treatment efficacy in unresectable hepatocellular carcinoma (uHCC).
Lirafugratinib: An ePoster post-hoc analysis from the ReFocus trial examining prior immunotherapy exposure and mucocutaneous adverse event risks.
Presentation Details
Rapid Oral Presentation:
Title: Rivoceranib in patients with pretreated metastatic thymic epithelial tumors: phase II multi-center KCSG LU23-09 (THRIVE) trial
Speaker: Sehhoon Park, M.D., Ph.D., Professor and Thoracic Medical Oncologist at Samsung Medical Center in Seoul, South Korea
Presentation No.: 4155RO
Session Title: Non-metastatic NSCLC and other thoracic malignancies
Session Date/Time: Oct. 26, 2026, 10:15 a.m. – 11:45 a.m. CET
Location: Burgos Auditorium – Hall 3
Poster Presentation:
Title: Impact of early antibiotic exposure on efficacy of camrelizumab plus rivoceranib versus sorafenib in patients with unresectable hepatocellular carcinoma (uHCC): a sub-analysis of CARES-310
Presentation No.: 1686P
Presentation Topic: Hepatocellular Carcinoma
Session Date/Time: Oct. 25, 2026, 12:00 p.m. – 12:45 p.m. CET
ePoster Presentation:
Title: Immune Checkpoint Inhibitors (ICI) and Risk of Mucocutaneous Adverse Events (mcAEs) on FGFR2 Inhibition: Post-Hoc Analysis of the Lirafugratinib (Lira) ReFocus Trial
Presentation No.: 1096eP
Presentation Topic: Developmental Therapeutics
Location: ePosters will be available via searchable screens located onsite in Hall 5
(Press release, Elevar Therapeutics, JUL 27, 2026, View Source [SID1234669446])